• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis backs off from 2016 date for testing Google autofocus lens

November 21, 2016 By Sarah Faulkner

Novartis backs off from 2016 date for testing Google autofocus lensNovartis (NYSE:NVS) is reportedly backing off a 2016 start date to test its autofocusing contact lens in clinical trials, but it told Reuters that the product is “progressing steadily” in its collaboration with Google (NSDQ:GOOGL).

In 2014, CEO Joe Jimenez said he hoped the lens would be on the market in 5 years and last year he said his company’s Alcon eye care unit was on track to begin clinical testing in 2016.

“It is too early to say when exactly human clinical trials for these lenses will begin,” a spokeswoman for the Basel-based drug-maker told Reuters. “This is a very technically complex process and both sides are learning as we go along. We will provide updates at the appropriate time,”

Novartis and Google inked a partnership 2 years ago to develop an autofocusing lens for people with presbyopia and a lens that can measure blood glucose levels in diabetes patients.

The noninvasive lenses for diabetic patients could present an alternative to finger-pricks and an autofocusing lens could help patients whose ability to focus degenerates as they age. The company has not commented on when testing for the diabetes lens will start, according to Reuters.

Since Google and Novartis landed a deal in 2014, Alcon’s sales have declined and it has undergone changes to its leadership team. New division head Mike Ball has been charged with halting the company’s revenue slide in case the unit is sold. But the spokeswoman said that did not prevent investment in projects such as the lens effort with Google.

“Advancing innovation such as the smart lens technology, is a key part of Alcon’s growth strategy,” the spokeswoman told the news outlet. “The ‘smart lens’ technology has the potential to transform eye care and further enhance our pipeline … in the contact lens and intraocular lens space.”

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Research & Development Tagged With: Google, Novartis

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS